Results 211 to 220 of about 67,560 (281)

Liver Fibrosis: Molecular Pathogenesis and Therapeutic Interventions

MedComm, Volume 7, Issue 5, May 2026.
We systematically summarized the etiologies, diagnostic approaches, and pathogenic mechanisms of liver fibrosis. Also, the therapeutic interventions for liver fibrosis were systematically classified into two main categories: etiological treatment and mechanism‐based antifibrotic therapies.
Jiaorong Qu, Wenqing Qin, Minghang Dong, Zhi Ma, Si Li, Runping Liu, Ranyun Chen, Changmeng Li, Xiaojiaoyang Li   +8 more
wiley   +1 more source

A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension. [PDF]

Exp Ther Med, 2019
Dang ZC, Tang B, Li B, Liu S, Ge RL, Li ZQ, Lu DX.   +6 more
europepmc   +1 more source

Post Activation Potentiation Is Greater in Human Triceps Brachii Versus Triceps Surae Muscles

Muscle &Nerve, Volume 73, Issue 5, Page 815-821, May 2026.
ABSTRACT Introduction/Aims Voluntary muscle contractions result in a temporary increase in twitch force, a phenomenon termed post activation potentiation (PAP). In rodents and other species, PAP is observed predominantly or exclusively in fast twitch muscles. However, it has been suggested that in humans, PAP occurs more or less independently of muscle
William S. Zoughaib, Madison J. Fry, Ahaan Singhal, Richard L. Hoffman, Andrew R. Coggan   +4 more
wiley   +1 more source

Are phosphodiesterase type 5 inhibitors associated with increased risk of melanoma?: A systematic review and meta-analysis. [PDF]

Medicine (Baltimore), 2018
Feng S, Zhou L, Liu Q, He Q, Liao B, Wei X, Li H, Wang K, Zhu Y.   +8 more
europepmc   +1 more source

Demonstration of a Heat-Stable Cyclic GMP Phosphodiesterase in the Medium of Physarum flavicomum [PDF]

, 1985
Lynch, Thomas J., Ross, Mark S.
core   +2 more sources

MBMA Bridging Models as a Tool for Exploration of Clinical Endpoints in Unstudied Indications

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Model‐based meta‐analysis (MBMA) offers a powerful framework for quantitatively integrating clinical trial data to inform drug development and decision‐making. In this study, a novel quantitative modeling approach using MBMA was proposed to project key efficacies of treatment in future Phase 2 or Phase 3 studies for an untested indication.
Mehrdad Javidi, Gregory E. Alexander, Teddy Kosoglou, An Vermeulen, Anna Beutler, Tasneam Shagroni, Chandni Valiathan   +6 more
wiley   +1 more source

Phosphodiesterase type 5 inhibitors usage and prostate cancer: a match-paired analysis. [PDF]

Transl Androl Urol, 2017
Machen GL, Rajab MH, Pruszynski J, Coffield KS.   +3 more
europepmc   +1 more source

Hederagenin Attenuates Cardiac Remodeling by Targeting Phosphodiesterase 9A

Phytotherapy Research, Volume 40, Issue 5, Page 2710-2729, May 2026.
ABSTRACT Background and Aim New therapeutic strategies for heart failure are urgently needed. The protective effects of cyclic guanosine monophosphate (cGMP)—protein kinase G (PKG) pathway on heart have been widely reported. Despite phosphodiesterase 9A (PDE9A) inhibitors combating cardiac remodeling, clinically available drugs are lacking. Hederagenin
Liqian Chen, Xinghong Zhou, Yanting You, Jieyu Chen, Baizhao Peng, Yijian Deng, Shuai Ji, Ying Yang, Xiaohu Chen, Huaxi Liu, Shuxuan Yang, Hiu Yee Kwan, Wen Jin, Lei Zhang, Yuegang Wang, Xiaoshan Zhao, Yanyan Liu   +16 more
wiley   +1 more source

Serum Proteomic Analysis Using Gel‐Based Liquid Chromatography Tandem Mass Spectrometry Reveals Differences Between Canine Oral Malignancies and Non‐Malignant Conditions

Veterinary Medicine and Science, Volume 12, Issue 3, May 2026.
This study establishes a GeLC‐MS/MS‐based serum proteomics workflow for canine oral oncology to differentiate malignancies from non‐malignant conditions. Comprehensive protein profiling, pathway analysis and protein–drug interaction mapping reveal candidate biomarkers and insights into the pathogenesis of canine oral cancers.
Sekkarin Ploypetch, Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop, Gunnaporn Suriyaphol   +4 more
wiley   +1 more source

Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies. [PDF]

Onco Targets Ther, 2018
Han X, Han Y, Zheng Y, Sun Q, Ma T, Dai L, Zhang J, Xu L.   +7 more
europepmc   +1 more source